Key Notes
- Sanofi is reportedly consulting advisers about a possible acquisition of Insmed, with no agreed deal announced.
- Insmed rose 20.9% by 3:01 pm ET, while Sanofi’s US-listed ADRs fell 2.3% and its Paris shares closed down 2.9%.
- Insmed recently raised its 2026 Brinsupri sales forecast to $1.35 billion to $1.4 billion.
Insmed shares surged Thursday after a report that Sanofi is considering buying the US drugmaker, whose rapidly growing lung-disease business would add a new source of sales to the French pharmaceutical group.
Sanofi (Nasdaq: SNY) is speaking with advisers as it evaluates a potential acquisition, Bloomberg reported, citing people familiar with the matter. Deliberations are continuing, and any deal could still be weeks away.
Insmed (Nasdaq: INSM) traded at $144.87, up 20.9%, at 3:01 pm ET on November 19. Sanofi’s US-listed American depositary receipts were at $46.03, down 2.3% at the same time. Its Paris-listed shares closed 2.9% lower at €83.79.
No Offer Terms Announced
The report did not establish an agreed acquisition or disclose an offer price. Sanofi said it does not comment on market rumors, while Insmed did not immediately respond to Reuters’ request for comment.
A purchase would give Sanofi two marketed respiratory treatments, Brinsupri and Arikayce, alongside Insmed’s development pipeline. The company’s commercial growth has accelerated as Brinsupri’s launch gains traction.
Brinsupri Drives Insmed’s Growth
Insmed reported third-quarter revenue of $524.4 million on October 29. Brinsupri contributed $400.1 million, up 29% from the previous quarter, while Arikayce generated $124.4 million, up 9% from a year earlier.
The company raised its 2026 Brinsupri revenue forecast to $1.35 billion to $1.4 billion, lifting the lower end from $1.25 billion. It also increased the bottom of its Arikayce forecast to $460 million, keeping the upper end at $470 million.
Insmed remained loss-making despite that growth. Its quarterly net loss narrowed to $100.3 million from $370 million a year earlier.
Disclaimer: MarketSpeaker content is provided for informational and educational purposes only and does not constitute financial or investment advice. Investing involves risk, including the possible loss of principal. Verify information independently and consult a qualified professional before making financial decisions.